Partners News SPL Medical announces collaboration with NanoEcho

30 September 2022

SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform. Initially NanoEcho is aiming for market approval for the detection of lymph node metastases in rectal cancer patients.

In NanoEcho’s method for diagnostics of rectal cancer lymph node metastases, modern ultrasound technology is used together with iron-oxide nanoparticles. For the clinical effectiveness of the system, the choice of the appropriate nanoparticle is essential.

Ferrotran®, the lymphotropic nanoparticle of SPL medical, is in advanced phase III for the detection of lymph node metastases for prostate cancer patients with Magnetic Resonance Imaging (MRI).

The Ferrotran® particle has been developed as a platform technology for various applications for the broad base of installed MRI scanners worldwide.

With this collaboration with NanoEcho the Ferrotran® platform technology will be extended also to modern ultrasound technologies.

“The extension of the scope of applicability of Ferrotran® to ultrasound technology demonstrates the wide power of our platform technology beyond the broad field of nano-MRI”, says Dr. Jürgen Feuerstein CEO for SPL Medical.

“We are very pleased to have established this collaboration with SPL medical. This is an important step in our journey. Based on our initial evaluation, the particle provided by SPL medical looks very promising for our application. Their expertise in the development and commercialization of nanoparticles is impressive and will be very beneficial for us at NanoEcho”, says Dr. Linda Persson CEO for NanoEcho.

Source: Ferrotran website

Related news items


Enzyre closes Series A financing round of €12M to advance pioneering diagnostic technology platform for hemophilia patients

2 November 2022

Enzyre has announced that it has successfully raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment, Takeda Ventures, and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.

read more

Successful matchmaking at Radboudumc Investment Day  

7 October 2022

On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.

read more

Radboudumc Investment Day 2022

26 September 2022

Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!

read more

Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI

1 December 2021

Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.

read more

Meet BabyChecker!

24 September 2021 On September 20th, 2021, Delft Imaging launched BabyChecker: an affordable and portable smartphone-based ultrasound solution. read more

ScreenPoint Medical raises $28 million for further development Series C funding led by Insight Partners

2 August 2021 ScreenPoint Medical has raised $28 million in a Series C financing. ScreenPoint Medical is a spin-off of the Radboudumc. read more